$OTLK THIS IS JUST THE BEGINNING FOR OUTLOOK THERAPEUTICS

If you are not familiar with the Stock, get to know it now, it has made investors a lot of money in the past 4 trading days, tripling in value. There is always concerns when it comes to such low cap companies but this rally is based on facts not speculation. After a extremely upbeat drug trial report it was upgraded to $12 the following day by Oppenheimer.
There is no need to worry about missing out on this rally as it has a very long way to g, it was 70% higher on Feb 18th.
A nice entry level is $3.50 just above resistance, with a take profit at $6 below the 200MA.


Average Analysts price target $7
Average Analysts rating BUY

Company Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.